Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2965)	8/10/2010 11:54:50 AM
From: Jibacoa	Respond to of 3722

SUPG is still bouncing up from the $2 level It was up 4.97% at 9:44am, but is up only 1.49% at present although still up in spite of the general market.<g> Volume remains low about 0.14x its ADV bigcharts.marketwatch.com It reported its 2ndQ results last week and a transcript of the CC can be seen at S.A.: seekingalpha.com The 2ndQ revenues although 31.25% lower on a sequential basis, were 65% better compared to the prior Yr., $9.9M vs. $6.0M in 2009. The increase in revenues was primarily related to the royalties form Dacogen, which increased 62% to $9.8 M vs. $6.0M.<g> The earnings were $0.01 vs. a loss of $0.04 in 2009 and the cash on hand as of June 30 was close to $107M million. They said that should be enough to enable them to advance the discovery and development of products in their pipeline without the need for extra financing. The Dacogen PIII trial in AML, was released, but the analysis of the results still continues. The primary endpoint of survival didn't achieve statistically significant superiority over the control arm in the trial, but a trend was evident and Eisai & JNJ intend to file a Marketing Authorization Applications for Dacogen in AML in the EU sometime next year.<g> Dacogen and Vidaza sales continue to grow and could be in the $700M range in 2010. Dacogen retains an approximate 40% share of the hypomethylation market in North America. JNJ's subsidiary Janssen-Cilag is selling the drug in more than 25 countries outside US, including China. The royalty revenue for Dacogen was revised upward and is expected to be up 17% from 2009. The guidance was also increased from $41M to $45M, to a revised range from $44 to $48M. Two weeks ago the FDA cleared SGI-110 IND and they are now planning to start a PI on patients with myelodysplastic syndromes. Data analysis from the PIb of amuvatinib, or MP-470 was completed in the quarter and the data will be presented at a major scientific meeting next year. They are planing a PII of this drug after consulting with their medical advisors and other opinion leaders. SGI-1776, is on schedule to begin a PI/II in refractory leukemias during the second half of this year. This will complement the ongoing PI in refractory prostate and lymphomas, for which the MTD has been achieved. The details of the preliminary data from this first-in-human prostate and lymphomas trial of SGI-1776 will be presented at a scientific conference next year. SGI-110 is a low volume, less than one milliliter, high concentration, subcutaneous product that will allow less frequent dosing schedules compared to currently marketed products. The ACTAY has been trimmed to $5.50 That still would be a good % gain from present levels.<g> But although the stock has plenty of room to run, I will still keep a TT at just $2.50 pending further developments.<g> bigcharts.marketwatch.com Bernard